Brainsway Ltd. (TASE:BRIN) today reported additional positive interim results in the clinical trial of its non-invasive Deep TMS (transcranial magnetic stimulation) treatment for Alzheimer's disease. The trial includes 24 patients in three groups of eight patients each: a control group, a group which received treatments at 1 Hertz frequency and a group that received treatments at 10 Hertz frequency.
The treatments lasted for eight weeks, and their efficacy was reviewed eight weeks later, using a range of standard cognitive measures for Alzheimer's.
All the patients handled the treatment well and suffered no side effects, except in one case in the control group, which the chief researcher believes was unrelated to the treatment.
The study found that more severely affected Alzheimer's patients who received the 10 Hertz treatment showed more significant improvement compared with patients with less cognitive impairment at the start of the study. The results showed a halt in cognitive deterioration, and even some improvement in patients compared with the control group and compared with patients who received treatment with 1 Hertz frequency.
Brainsway's share price rose 2% by mid-afternoon to NIS 17, giving a market cap of NIS 200 million.
Published by Globes [online], Israel business news - www.globes-online.com - on September 27, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011